HSP90AA1 and non-small cell lung carcinoma: Interestingly, the same combination of drugs, ganetespib and docetaxel, has been used in a Phase III trial of advanced non-small cell lung cancer and showed better safety profiles when compared to HSP90 first generation inhibitors [125].